Maria Stefania Sromek

Dr. Maria Stefania Sromek

Department of Cancer Biology Maria Sklodowska-Curie National Research Institute of Oncology Warsaw Poland
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2017 in Cellular Oncology
Verified
Journal Article
Closed access
PDF file
MSMaria Stefania Sromek
Maria Stefania Sromek
MGMaciej Glogowski
Maciej Glogowski
MCMagdalena Chechlinska
Magdalena Chechlinska
MKMariusz Kulińczak
Mariusz Kulińczak
LSLukasz Michal Szafron
Lukasz Michal Szafron
JSJan Konrad Siwicki
Jan Konrad Siwicki

1 January 2007 in Cancer Investigation
Verified
Journal Article
Closed access
ZPZ. Paszko
Z. Paszko
MSMaria Stefania Sromek
Maria Stefania Sromek
MCM. Czetwertynska
M. Czetwertynska
ESE. Skasko
E. Skasko
DCD. Czapczak
D. Czapczak
IKI. Kozlowicz-Gudzinska
I. Kozlowicz-Gudzinska
We aimed to investigate the occurrence and types of pathogenic mutations in the RET gene in patients with MTC of the Central Poland population and in their relatives. DNA was extracted from the peripheral blood lymphocytes of a total of 330 persons, including 235 MTC patients and 95 of their unaffected kindred's. Exons 10, 11, 13, 14, 15 and 16 of the RET gene were amplified by PCR and sequenced. Sixty-seven people were found to carry pathogenic, germline mutations in the RET gene. In exon 10, C609F, C609R and C609Y (3 families), C618G, C618F (2 families), and C620G (4 families) mutations were identified. In exon 11, C634R (8 families) and C649L mutations (1 patient) were found. Five families carried Y791F mutation in exon 13. One patient with PTC revealed the presence of a Y791F mutation. In 3 families, exon 14 of the RET gene harbored the following mutations: V804L (1 patient), E819K (1 patient) and R844Q (1 patient). In 1 family, the S891A mutation was identified in exon 15, 3 families were found to carry mutations in exon16, R912P in 1 family and M918T in 2 families. In summary, of the 235 patients affected by MTC, 46 (19.6%) carried pathogenic RET gene mutations, 1 patient with RET mutation had kidney carcinoma, and 1 had PTC. The results show the occurrence of a variety of mutations prevalent in patients with MTC in the population of Central Poland. These results may contribute to a better diagnosis of medullary thyroid carcinoma.

25 October 2019 in Cancers
Verified
Journal Article
Open access
PDF file
MZMichalina Zajdel
Michalina Zajdel
GRGrzegorz Rymkiewicz
Grzegorz Rymkiewicz
MSMaria Stefania Sromek
Maria Stefania Sromek
MCMaria Cieslikowska
Maria Cieslikowska
PSPawel Swoboda
Pawel Swoboda
JSJan Konrad Siwicki
Jan Konrad Siwicki
Primary central nervous system lymphoma (PCNSL) is a rare, highly aggressive, extranodal form of non-Hodgkin lymphoma, predominantly diagnosed as primary diffuse large B-cell lymphoma of the central nervous system (CNS DLBCL). Fast and precise diagnosis of PCNSL is critical yet challenging. microRNAs, important regulators in physiology and pathology are potential biomarkers. In 131 patients with CNS DLBCL and with non-malignant brain lesions (n-ML), miR-21, miR-19b and miR-92a, miR-155, miR-196b, miR-let-7b, miR-125b, and miR-9 were examined by RT-qPCR in brain biopsy samples (formalin-fixed paraffin-embedded tissues, FFPET; CNS DLBCL, n = 52; n-ML, n = 42) and cerebrospinal fluid samples (CSF; CNS DLBCL, n = 30; n-ML, n = 23) taken for routine diagnosis. FFPET samples were split into study and validation sets. Significantly higher CSF levels of miR-21, miR-19b, and miR-92a were identified in PCNSL but not in n-ML, and differentiated PCNSL from n-ML with 63.33% sensitivity and 80.77% specificity. In FFPETs, miR-155 and miR-196b were significantly overexpressed and miR-let-7b, miR-125b, and miR-9 were downregulated in PCNSL as compared to n-ML. Combined miR-155 and miR-let-7b expression levels in FFPETs discriminated PCNSL and n-ML with a 97% accuracy. In conclusion, tissue miR-155, miR-196b, miR-9, miR-125b, and miR-let-7b expression profiles differentiate PCNSL from n-ML. PCNSL CSFs and the relevant biopsy samples are characterized by specific, different microRNA profiles. A logistic regression model is proposed to discriminate between PCNSL and non-malignant brain lesions. None of the examined microRNAs influenced overall survival of PCNSL patients. Further ongoing developments involve next generation sequencing-based profiling of biopsy and CSF samples.

3 June 2010 in Endocrine Pathology
Verified
Journal Article
Closed access
PDF file
MSMaria Stefania Sromek
Maria Stefania Sromek
MCMalgorzata Czetwertyńska
Malgorzata Czetwertyńska
ESElzbieta Skasko
Elzbieta Skasko
JZJoanna Zielińska
Joanna Zielińska
DCDorota Czapczak
Dorota Czapczak
JSJan Steffen
Jan Steffen

1 April 2018 in Endocrine-Related Cancer
Verified
Journal Article
Closed access
PDF file
MKMarta Kaczmarek-Ryś
Marta Kaczmarek-Ryś
KZKatarzyna Ziemnicka
Katarzyna Ziemnicka
APAndrzej Pławski
Andrzej Pławski
BBBartlomiej Budny
Bartlomiej Budny
MMMichał Michalak
Michał Michalak
RSRyszard Slomski
Ryszard Slomski
The clinical course of medullary thyroid carcinoma (MTC) associated with the MEN2A syndrome as well as of sporadic MTC shows considerable heterogeneity. The disease picture varies not only between the sameRETproto-oncogene mutation carriers but also among sporadic MTC patients with noRETgerminal mutations, which suggests the involvement of additional modulators of the disease. However, genetic factors responsible for this heterogeneity of the MTC clinical course still remain unknown. The aim of this study was to determine if polymorphic variants or specific haplotypes of theRETgene may modify the MTC clinical course. We genotyped the followingloci:c.73+9277T>C, c.135G>A, c.1296A>G, c.2071G>A, c.2307T>C, c.2508C>T and c.2712C>G in 142 MTC patients and controls. We demonstrated considerable differences in the genotypes distribution within c.73+9277T>C, c.135G>A and c.2307T>Cloci. Our results show that the c.73+9277T variant associated with a decreased activity of the MCS+9.7RETenhancer is rare in hereditary MTC patients with primary hyperparathyroidism, and thus, may influence the MTC clinical picture. The decreased activity of theRETpromoter enhancer reducesRETexpression level and may counterbalance the activating mutation in this gene. Frequent co-occurrence of the c.73+9277T allele with p.E768D, p.Y791F, p.V804M or p.R844QRETmutations may be associated with their attenuation and milder clinical picture of the disease. Haplotypes analysis showed that C-G-A-G-T-(C)-C (c.73+9277T>C – c.135G>A – c.1296A>G – c.2071G>A – c.2307T>G – (c.2508C>T) – c.2712C>G) alleles combination predisposes to pheochromocytomas and primary hyperparathyroidism. We consider thatREThaplotypes defining may become an auxiliary diagnostic tool in MTC patients.

21 September 2021 in Biomolecules
Verified
Journal Article
Open access
PDF file
MSMaria Stefania Sromek
Maria Stefania Sromek
GRGrzegorz Rymkiewicz
Grzegorz Rymkiewicz
APAgnieszka Paziewska
Agnieszka Paziewska
LSLukasz Michal Szafron
Lukasz Michal Szafron
MKMaria Kulecka
Maria Kulecka
JSJan Konrad Siwicki
Jan Konrad Siwicki
The diagnosis of primary central nervous system (CNS) lymphoma, which is predominantly of the diffuse large B-cell lymphoma type (CNS DLBCL), is challenging. MicroRNAs (miRs) are gene expression-regulating non-coding RNAs that are potential biomarkers. We aimed to distinguish miR expression patterns differentiating CNS DLBCL and non-malignant CNS diseases with tumor presentation (n-ML). Next generation sequencing-based miR profiling of cerebrospinal fluids (CSFs) and brain tumors was performed. Sample source-specific (CSF vs. brain tumor) miR patterns were revealed. Even so, a set of 17 miRs differentiating CNS DLBCL from n-ML, no matter if assessed in CSF or in a tumor, was identified. Along with the results of pathway analyses, this suggests their pathogenic role in CNS DLBCL. A combination of just four of those miRs (miR-16-5p, miR-21-5p, miR-92a-3p, and miR-423-5p), assessed in CSFs, discriminated CNS DLBCL from n-ML samples with 100% specificity and 67.0% sensitivity. Analyses of paired CSF-tumor samples from patients with CNS DLBCL showed significantly lower CSF levels of miR-26a, and higher CSF levels of miR-15a-5p, miR-15b-5p, miR-19a-3p, miR-106b-3p, miR-221-3p, and miR-423-5p. Noteworthy, the same miRs belonged to the abovementioned set differentiating CNS DLBCL from non-malignant CNS diseases. Our results not only add to the basic knowledge, but also hold significant translational potential.